JPRN-UMIN000006273已完成1 期
A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation - A phase I study of pemetrexed and gefitinib in chemotherapy naive elderly patients with non- small cell lung cancer harboring EGFR mutation
ational Hospital Organization Kyushu Medical Center Department of Respiratory Medicine0 个研究点目标入组 11 人开始时间: 2011年9月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Serious infections 2)Serious clinical problems 3)Interstitial pneumonia/lung fibrosis on chest CT 4)Active concomitant malignancy 5)Symptomatic brain metastasis 6)Massive pericardial, pleural effusion, ascites 7)Previous drug allergy 8)Those judged to be not suitable by the attending physician
研究者
相似试验
已完成
2 期
A Phase II Study of Pemetrexed and Gefitinib in Chemotherapy Naive Patients with Non-Small Cell Lung Cancer Harboring Mutations of EGFRon-Small Cell Lung CancerJPRN-UMIN000003808Osaka Lung Cancer Study Group26
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33
已完成
2 期
Phase II trial of gefitinib plus pemetrexed after the relapse to gefitinib in the patients with non-small-cell lung cancer harboring EGFR gene mutations.SCLCJPRN-UMIN000010709Hanshin-Saga Collaborative Cancer Study Group45
未知
2 期
A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsJPRN-jRCT1080221763Eli Lilly Japan K.K.
进行中（未招募）
不适用
En fase II undersøgelse af pemetrexed og gemcitabin til behandlingsresistente patienter med KRAS muteret metastaserende colorectal cancerTreatment resistant metastatic colorectal cancer with KRAS mutationsMedDRA version: 13.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10010035Term: Colorectal cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018700-90-DKVejle Hospital